|
15 Sep 2025 |
Hindustan Unilever
|
Consensus Share Price Target
|
2581.00 |
2722.53 |
- |
5.48 |
buy
|
|
|
|
|
21 Jul 2020
|
Hindustan Unilever
|
Motilal Oswal
|
2581.00
|
2550.00
|
2248.50
(14.79%)
|
|
Buy
|
|
|
21st July 2020 Hindustan Unilever (HUVR) reported 5% beat on sales and ~10% beat on EBITDA and PAT v/s our estimates. The outlook is gradually improving, with the discretionary part of the portfolio (15% of sales) gradually seeing recovery. In a period of relative normalcy, HUVR (as has been the case in recent years) is likely to report superior earnings growth, which has led us to margins stood at 51.8% (220bp contraction YoY), while EBITDA margins contracted by 110bp YoY to 25%. sales declined 7% YoY in v/s est. The segmental EBIT margin up by 20bp YoY for F&R;, but down by 140bp/150bp for HC/PC. to the P&L; A/c was approved by its Shareholders in 2016. The Board approved the distribution of the Reserves to its Shareholders by means of a Special Dividend of INR9.50/share.
|
|
21 Jul 2020
|
Hindustan Unilever
|
Prabhudas Lilladhar
|
2581.00
|
2278.00
|
2221.50
(16.18%)
|
Target met |
Hold
|
|
|
marketing and innovations. HUL seems well placed to gain from 1) increased consumer focus on hygiene increasing demand for personal wash, Detergents and Hygiene 2) Synergy benefits in GSK as the current...
|
|
16 Jul 2020
|
Hindustan Unilever
|
Axis Direct
|
2581.00
|
2386.00
|
2334.55
(10.56%)
|
Target met |
Buy
|
|
|
We recommend a BUY on HINDUSTAN UNILEVER with a Target Price of Rs 2,386 an upside of 6% from CMP of Rs. 2,253 and Stop Loss Rs 2,185.
|
|
29 Jun 2020
|
Hindustan Unilever
|
Ventura
|
2581.00
|
|
2180.00
(18.39%)
|
|
Hold
|
|
|
Annual Report Analysis
|
|
12 Jun 2020
|
Hindustan Unilever
|
Motilal Oswal
|
2581.00
|
2400.00
|
2107.25
(22.48%)
|
Target met |
Buy
|
|
|
HUVRs volume and earnings growth in recent years has been far superior to that of its Consumer peers; the company is likely to continue to do well over the medium to long term as well. However, as the laggard Soaps segment could now see higher growth in terms of both volume and premiumization (hand washes, sanitizers, and body washes are at a much higher price index than soaps), the companys overall earnings growth Mr Mehta believes the Detergents and Home Care segments are also bound to do well amid the pandemic as well as later, albeit not at as accentuated a pace as Rising demand has been witnessed for immunity-building products and in-home consumption is also growing.
|
|
11 May 2020
|
Hindustan Unilever
|
Hem Securities
|
2581.00
|
2410.00
|
2011.55
(28.31%)
|
Target met |
Accumulate
|
|
|
Hindustan Unilever Limited (HUL) is India's largest Fast Moving Consumer Goods company with a heritage of over 80 years in India. With over 35 brands spanning 20 distinct categories such as soaps, detergents, shampoos, skin care, toothpastes, deodorants, cosmetics, tea, coffee, packaged foods, ice cream, and water purifiers, the Company is a part of the everyday life of millions of consumers across India. Its portfolio includes leading household brands such as Lux, Lifebuoy, Surf Excel, Rin, Wheel, Fair & Lovely, Pond's, Vaseline, Lakm, Dove, Clinic Plus, Sunsilk, Pepsodent, Closeup, Axe, Brooke Bond, Bru, Knorr, Kissan, Kwality Wall's and Pureit. HUL is a...
|
|
08 May 2020
|
Hindustan Unilever
|
Sharekhan
|
2581.00
|
2305.00
|
2048.00
(26.03%)
|
Target met |
Buy
|
|
|
The GSK Group sold a 5.7% stake (13.37 crore shares) in Hindustan Unilever Limited (HUL) through multiple block deals in the open market at an average price of Rs. 1,902 per share. The stock has corrected by ~16% from its high and its currently trading at 48.1x its FY2022E earnings. GSK Group selling the stake has reduced supply overhang on the stock and the current valuations factors in a sluggish Q4 due to supply disruption caused by the nationwide lockdown in the fag-end of the quarter. We expect supply disruption to sustain in the coming months till the time the nation recovers from the pandemic situation. Thus, H1FY2021 would see HUL's sales significantly...
|
|
08 May 2020
|
Hindustan Unilever
|
Sharekhan
|
2581.00
|
2305.00
|
2089.45
(23.53%)
|
Target met |
Buy
|
|
|
The GSK Group sold a 5.7% stake (13.37 crore shares) in Hindustan Unilever Limited (HUL) through multiple block deals in the open market at an average price of Rs. 1,902 per share. The stock has corrected by ~16% from its high and its currently trading at 48.1x its FY2022E earnings. GSK Group selling the stake has reduced supply overhang on the stock and the current valuations factors in a sluggish Q4 due to supply disruption caused by the nationwide lockdown in the fag-end of the quarter. We expect supply disruption to sustain in the coming months till the time the nation recovers from the pandemic situation. Thus, H1FY2021 would see HUL's sales significantly...
|
|
07 May 2020
|
Hindustan Unilever
|
Geojit BNP Paribas
|
2581.00
|
2200.00
|
2089.45
(23.53%)
|
Target met |
Hold
|
|
|
Company posted 9.4% declines in Q4FY20 revenue to Rs. 9,011cr, primarily impacted by breakage of supply chain (company plants now running at 70-75% utilization) and subdued demand amidst nationwide lockdown post mid-March. Company witnessed weaker revenue across all three segments with Beauty & Personal Care segment leading the declines (-13.5% YoY) while followed by Food & Refreshments (-6.7%) and Home Care (-4.3%). For FY20, company managed to achieve 1.5% YoY growth in...
|
|
06 May 2020
|
Hindustan Unilever
|
Way2Wealth
|
2581.00
|
|
1992.05
(29.57%)
|
|
Hold
|
|
|
Gross margin expanded by ~138 bps to 52.43% Y-o-Y on account of benign commodity prices. EBITDA decreased by 11% Y-o-Y to `2,065 crs in Q4FY20 led by higher ad spends, partly offset by lower staff costs and other expenses. Reported EBITDA margin stood at 22.9% as opposed to 23.9% in Q4FY19, contracted by 40 bps (160bps...
|